Douglas N. Robins, M.D. Ameriderm Research

Transcription

1 Curriculum Vitae Douglas N. Robins, M.D. Ameriderm Research Office Address: Leavitt Medical Associates of Florida (DBA) Advanced Dermatology and Cosmetic Surgery Ameriderm Research 4100 Southpoint Dr. suite 1 Jacksonville, FL P : F : drdrobins@ameridermresearch.com Leavitt Medical Associates of Florida (DBA) Ameriderm Research 725 West Granada Blvd Suite 44 Ormond Beach, FL P: F: /09 Current Leavitt Medical Associates of Florida (DBA) Ameriderm Research 4100 Southpoint Dr. Suite 1 Jacksonville, FL /00 7/09 North Florida Dermatology Associates, P.A Riverside Avenue Jacksonville, FL /00 Private Practice Washington, D.C. Assistant Clinical Professor of Dermatology George Washington University Medical School Education: Washington and Lee University Lexington VA Bachelor of Science Degree Graduate 1965 George Washington University Medical School Washington D.C. Page 1 of 8

2 Doctorate of Medicine Graduate 1969 Internship: Washington Hospital Center Washington D.C Residency: New York University Bellevue Medical Center New York, NY Department of Dermatology Chief Resident and Clinical Instructor of Dermatology Certification: Hospital Privileges: American Board of Dermatology Specialty Dermatology Since 1974 Baptist Medical Center Jacksonville, FL Active since 2000 Memberships: Best Doctors in America Database Medical Society of the District of Columbia Alternate Delegate to the American Medical Association Washington, D.C. Dermatologic Society (secretary President ) Phi Delta Epsilon Medical Fraternity (President-Washington DC Graduate Club ) American Society for Dermatologic Surgery American Academy of Dermatology Duval County Medical Society St. Johns County Medical Society Jacksonville Dermatologic Society (President 2007) Page 2 of 8

3 Florida Medical Association American Medical Association Noah Worcester Dermatology Society Florida Society of Dermatology and Dermatologic Surgery -Membership Chairman ; -Vice President Presidential Council National Psoriasis Foundation Annenberg Circle Dermatology Foundation Publication: Basal Cell Carcinoma Occurring in Scar Tissue Following Excision of a Parotid Gland Pleomorphic Adenoma. Dermatologic Surgery, 30: Alopecia Universalis: Hair Growth Following Initiation of Simvastatin and Eztimibe Therapy. Journal of Drugs in Dermatology 6: Intramuscular Triamcinolone A Safe, Effective and Underutilized Dermatologic Therapy. Journal of Drugs in Dermatology, 8: Research Experience: PI: A multicenter, open registry of patients with psoriasis candidates for systemic therapy including biologics,2011 PI: Phase IIb randomized, multicenter, placebo controlled, double blind parallel group dose finding study in patients with plaque psoriasis, 2011 PI: Effect of XXX Topical Suspension on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 17 Years) with Scalp Psoriasis, 2010 PI: A Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of XXX in Patients with Severe Recalcitrant Nodular Acne, 2009 PI: A Phase III, Multicenter, Randomized, Double-Blind Study Evaluating the Safety of XXX Topical Solution versus Vehicle in Subjects with Mild to Moderate Onychomycosis of the Toenails, 2009 Page 3 of 8

4 PI: A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy, Safety and Tolerability of XXX in Adults with a Diagnosis of Atopic Dermatitis (AD) with Moderate to Very Severe Pruritus, 2009 PI: A Phase IV Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of XXX in Adult Patients with Moderate to Severe Plaque Psoriasis With Involvement of the Scalp, 2007 PI: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens of XXX to Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis, 2007 Sub-Investigator: A Randomized, Double-Blind, Multiple Site, Placebo- Controlled Study Comparing XXX Topical Gel to XXX Topical Gel 1% Clindamycin 5% Benzoyl Peroxide in the treatment of Moderate to Severe Acne Vulgaris,2007 Sub-Investigator: A Double-Blind, Randomized, Parallel-Group, Placebo- Controlled, Multi-Center Study to Evaluate the Safety and Clinical Equivalence of Generic XXX Gel 1% to Metrogel % and both Active Treatments to a Vehicle Control in the Treatment of Rosacea Lesions, 2007 Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multi-Site Clinical Study to Evaluate the Bioequivalence of XXX Ointment 0.005% to XXX 0.005% in patients with Moderate to Severe Plaque Psoriasis,2007 Sub-Investigator: A Randomized, Double-Blind, Multiple-Site, Placebo- Controlled Study Comparing XXX Topical Gel XXX Topical Gel 1% XXX\ in the Treatment of Severe Acne Vulgaris, 2007 Sub-Investigator: A Multi-Center, Randomized, Double-Blind, Double-Dummy, Vehicle-Controlled sequential cohort study to determine the safety of XXX 0.025% and 0.05% Topical Gel in Patients with Actinic Keratosis, 2006 PI: The Evaluation of Biomarkers in Patients with Active Psoriasis. Research Sample Bank, Inc., 2006 Sub-Investigator: Patients Using MICRO Properly; An Open-Label, Community Based Phase Four Study to Assess Facial Acne Improvement with Use of XXX Microsphere, 0.04% or 0.1% in a Pump Dispenser, 2006 PI: Observational Post-Marketing Safety Surveillance Registry of XXX for the Treatment of Psoriasis, 2006 Page 4 of 8

5 Sub-Investigator: A Randomized, Evaluator Blinded, Vehicle-Controlled Multi- Center Study of the Safety and Efficacy of 4% XXX Cream Versus its Vehicle Versus XXX Cream in the Treatment of Actinic Keratosis, 2006 PI: XXX Spray Community based Research Assessment (COBRA) Trial, 2006 PI: Assessment and Tracking of Long-Term XXX Safety., 2005 PI: A Phase 3, Long-Term, Open Label Study to Evaluate the Safety of Twice Daily XXX Cream-B 0.1% in the Treatment of Psoriasis, 2005 Sub-Investigator: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of XXX Ointment fir the Treatment of Atopic Dermatitis (APPLES), 2005 Sub-Investigator: A Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety and Efficacy of Ethanol-Free XXX Foam, 0.05% in the Treatment of Moderate to Severe Atopic Dermatitis, 2005 Sub-Investigator: A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of XXX Foam, 2% versus XXX 2% Cream in the Treatment if Seborrheic Dermatitis, 2005 PI: XXX Epidemiologic Study of Psoriasis Outcomes and Safety Events in Patients with Chronic Moderate to Severe Plaque Psoriasis, 2005 PI: Measuring Acne Outcomes in a Real-World Experience Trial (MORE), 2005 PI: A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability if XXX in Subjects with Chronic Plaque Psoriasis Requiring Systemic Therapy, 2005 PI: A Phase 3, Multicenter Study of the Efficacy and Safety of Long Term Treatment in Subjects with Moderate to Severe Chronic Plaque Psoriasis, 2005 Sub-Investigator: The Phase III Programme of XXX In Psorisais, 2004 PI: A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Clinical Study with XXX, 2004 PI: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of XXX A Humanized Monoclonal Antibody to Integrin Alpha V Beta 3, Administered by Subcutaneous Injection to Adults with Plaque Psoriasis, 2004 Page 5 of 8

6 PI: A Study to Evaluate the Safety of patients with Psoriasis Treated with XXX PI: A Phase II Extension Study of Two Dosing Schedules of XXX in Subjects with Moderate to Severe Chronic Plaque Psoriasis, 2004 Sub-Investigator: A Multicenter, Randomized, Double-Blind, Placebo- Controlled Clinical Trial to Determine the Effects of XXX Modified-Release Capsules Administered Once Daily for the Treatment of Rosacea, 2004 Sub-Investigator: A Phase 3, Randomized, Double-Blind Study Comparing Twice Daily XXX Cream 0.03% Versus Cream Vehicle in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects., 2004 Sub-Investigator: C.L.E.A.R. A Community-Based Trial of XXX in the Treatment of Rosacea, 2004 Sub-Investigator: Phase IIIb, Open-Label Effectiveness and Safety Study of XXX 5% Topical Cream in the Treatment of Actinic Keratosis, 2004 Sub-Investigator: An Open-Label 18 Month Safety of XXX Cream for the Treatment of Actinic Keratoses, 2004 PI: An Open-Label, Multicenter Study to Evaluate the safety of 1.0mg/kg Subcutaneous XXX in Adults with Moderate to Severe Plaque Psorisais Including Those Who Are Receiving Concomitant Antipsoriatic Therapies or Have Recently Transitioned from Systemic Therapies, 2003 PI: A Phase II Study of Two Dosing Schedules of XXX in Subjects with Moderate to Severe Chronic Plaque Psoriasis, 2003 Sub-I: A Multicenter, Randomized, Placebo-Controlled Phase 2 Study Evaluating the Effect of XXX or XXX Treatment Compared to Placebo in Patients with Psoriasis, 2002 Sub- Investigator: An Open Label, Multi-Center Study to Evaluate the Safety and Tolerability of Intramuscular Administration of XXX in Subjects with Chronic Plaque Psoriasis who Have Completed Studies., 2002 Sub-Investigator: A Phase III, Mulit-Center, Open Label Study of the Safety of XXX Purified Neurotoxin Complex for the Treatment of Primary Axillary Hyperhidrosis, 2002 Page 6 of 8

7 Sub-Investigator: A Multi-Center, Open-Label Safety of XXX 4.5 mg Capsules Once Daily in patients with Moderate to Very Severe Psoriasis Treated for Up to One Year Followed by a 12-Week Post Treatment Follow-Up Period, 2002 Sub-Investigator: A 6 Month, Randomized, Multi-Center, Parellel-Group, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of XXX Cream 1% BID vs. Standard of Care in Management of Mild to Severe Atopic Dermatitis in Children 3 Months to 11 Years, 2001 Sub-Investigator: A Phase III Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the safety and Efficacy of Repeated Treatment with One of Two Dosages of xxx (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Primary Axillary Hyperhidrosis, 2001 PI: A Phase II, Randomized, Placebo-Controlled, Double-Blind Study of XXX, a Humanized Monoclonal Antibody the Binds to the CD2 Receptor, Administered by a Subcutaneous Injection to Adults with Plaque Psoriasis,2001 Sub-Investigator: A Phase III Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of XXX 5% Cream for the Treatment of Basal Cell Carcinoma, 2001 Sub-Investigator: A Phase III Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of XXX 5% Cream Applied Once Daily 2 Days per Week for the Treatment of Actinic Keratoses on the Head,2001 Sub-Investigator: A Phase III Vehicle-Controlled, Double-Blind Study To Assess the Safety and Efficacy of XXX 5% Cream of the Treatment of Superficial Basal Cell Carcinoma, 2000 Sub-Investigator: A Phase III Double-Blind, Dose Comparison, Retreatment Study to Evaluate the Efficacy of Intramuscular Administration of XXX in Subjects with Chronic Plaque Psoriasis Who Have Previously Completed, 2002 Sub-Investigator: A Phase III Multi-Center, Randomized, Parallel-Group, Safety Study in Pediatric Subjects with Atopic Dermatitis, Treated Once Daily for Three Weeks with XXX Cream, XXX Ointment, or XXX Lotion, 2000 Sub-Investigator: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Evaluate the Efficacy and Safety of Intramuscular Administration of XXX in Subjects with Chronic Plaque Psoriasis, 2000 Sub-Investigator: A Phase IV, Multi-Center, Open-Label Safety Study of XXX Cream in Pediatric Patients with Tinea Cruris, 2000 Page 7 of 8

8 Sub-Investigator: A Phase III Open-Label Study of XXX Ointment in Pediatric Patients with Atopic Dermatitis, 2000 Sub-Investigator: A Phase III, Open-Label Study to Evaluate The Safety Of Topically Applied XXX Ointment For The Treatment of Atopic Dermatitis, 1999 Sub-Investigator: A Phase IV Multi-Center, Open-Label Safety of XXX lotion in Pediatric Patients with Atopic Dermatitis, 1999 Sub-Investigator: A Phase III Open-Label Study of XXX Ointment in Pediatric Patients with Atopic Dermatitis Schering-Plough Research Institute, 1999 Sub-Investigator: A Phase IV Multi-Center, Open label Safety Study of XXX Cream in Pediatric Patients with Tinea Pedis, 1999 Sub-Investigator: A Phase III Open-Label Study of XXX Ointment in Pediatric Patients with Atopic Dermatitis, 1999 Clinical Trail Sponsors: Abbott Pharmaceuticals; Amgen Inc.; Astellas Pharmaceutical Inc.; Briogen Idea; Cipher Pharmaceuticals, Inc.; Conceits Corporation; Dow Pharmaceutical Sciences, Inc.; Galderma Laboratories; Genentech Inc; Glenmark Pharmaceuticals Inc.; Hill Dermaceuticals Inc.; Johnson & Johnson; KV Pharmaceutical Company; MedImmune Inc., Peplin Ltd.; Research Sample Bank Inc.; Schering-Plough Research Institute Taisho Pharmaceutical R & D, Inc.; Tolmar Inc.; Vertex Pharmaceuticals; Clinical Indications: Actinic Keratosis, Acne Vulgaris, Rosacea, Atopic Dermatitis, Psoriasis, Seborrheic Dermatitis, Onychomycosis Page 8 of 8